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Paula Jaime-Sanchez,1 Iratxe Uranga-Murillo,1 Rosa del Campo,7 Pablo Pelegrı́n,15 Eric Camerer,19
Luis Martı́nez-Lostao,1,8,13,14 Guillermo Muñoz,8 José A. Uranga,9 Anabel Alcalde,4,21 Eva M. Galvez,6 Angel Ferrandez,11
Phillip I. Bird,18 Sunil Metkar,10 Maykel A. Arias,6,22,* and Julian Pardo1,12,13,14,20,23,*
1Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain
2Department of Pharmacology and Physiology, Faculty of Health and Sports Sciences, University of Zaragoza, 22002 Huesca, Spain
3Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program,
Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L’Hospitalet de Llobregat, Barcelona, Spain
4Department of Pharmacology and Physiology, Faculty of Veterinary, University of Zaragoza, 50013 Zaragoza, Spain
5Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona
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https://doi.org/10.1016/j.celrep.2020.107847SUMMARYIf not properly regulated, the inflammatory immune response can promote carcinogenesis, as evident in colo-
rectal cancer (CRC). Aiming to gain mechanistic insight into the link between inflammation and CRC, we
perform transcriptomics analysis of human CRC, identifying a strong correlation between expression of
the serine protease granzyme A (GzmA) and inflammation. In a dextran sodium sulfate and azoxymethane
(DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate
gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithe-
lial-to-mesenchymal transition. Mechanistically, extracellular GzmA induces NF-kB-dependent IL-6 produc-
tion in macrophages, which in turn promotes STAT3 activation in cultured CRC cells. Accordingly, colon tis-
sues from DSS/AOM-treated, GzmA-deficient animals present reduced levels of pSTAT3. By identifying
GzmA as a proinflammatory protease that promotes CRC development, these findings provide information
on mechanisms that link immune cell infiltration to cancer progression and present GzmA as a therapeutic
target for CRC.Cell Reports 32, 107847, July 7, 2020 ª 2020 The Author(s). 1




Colorectal cancer (CRC) is the second-leading cause of cancer
cell death in developed countries and the third-most common
cancer. If not detected early and surgically removed, pharmaco-
logical treatment has low efficacy and resistance/recurrence
often occurs. A better understanding of the mechanisms
involved in CRC development may identify novel targets and
improve the current therapies against this lethal cancer.
Chronic inflammation represents an adverse prognostic fac-
tor for the progression of solid tumors like CRC. It is well
known that patients suffering from ulcerative colitis (UC)
have a higher risk of CRC (Bernstein et al., 2001; Eaden
et al., 2001). Inflammation is also involved in sporadic and he-
reditary CRC (Crusz and Balkwill, 2015; Fearon and Vogel-
stein, 1990; Mantovani, 2018; Shalapour and Karin, 2015).
The connection between inflammation and tumorigenesis is
mediated by cells of the innate and adaptive immune system,
including macrophages, eosinophils, innate lymphoid cells
(ILCs), and specific subsets of CD4+ T cells (Kirchberger
et al., 2013; Lasry et al., 2016; Powell et al., 2017; Shalapour
and Karin, 2015). Tumorigenesis is also influenced by the
composition of the gut microbiota (Brennan and Garrett,
2016; Powell et al., 2017). Reactive oxygen species (ROS);
lipid mediators produced by cyclooxygenase activity, such
as prostaglandin E2 (PGE2); and several proinflammatory cy-
tokines are involved in CRC development (Lasry et al., 2016;
Shalapour and Karin, 2015). All these molecules contribute
to epithelial cell transformation and tumor progression
through the activation of genetic and signaling pathways,
including nuclear factor kB (NF-kB), pSTAT3 (phospho-Signal
transducer and activator of transcription 3), Wnt, b-catenin, or
K-ras (Kaler et al., 2009; Karin, 1998; Li and Laterra, 2012;
Shalapour and Karin, 2015; Shenoy et al., 2012; Yu et al.,
2009). However, little is known about the molecular mecha-
nism or mechanisms by which the immune system orches-
trates the production of these proinflammatory factors during
gut inflammation and CRC. Thus, pharmacological regulation
of inflammation to prevent and/or improve CRC treatment is
nonspecific and associated with serious side effects related
to infection and (paradoxically) tumor progression (Yang
et al., 2017).
Granzymes (Gzms) are a family of serine proteases (5 in human
and 11 in mice) mainly expressed by cytotoxic cells (natural killer
[NK] cells and cytolytic CD8+ T cells). Some members of this
family are present in other immune cells, like CD4+ T cells, mac-
rophages, basophils, or mast cells, and non-immune cells, like
chondrocytes, keratinocytes, and pneumocytes (Afonina et al.,
2010; Arias et al., 2017; Martı́nez-Lostao et al., 2015; Turner
et al., 2019; Voskoboinik et al., 2015). SomeGzms exert their bio-
logical effects by inducing death of tumor or virus-infected cells
(Chowdhury and Lieberman, 2008) after being delivered intracel-
lularly by the pore-forming protein perforin (Bovenschen and
Kummer, 2010; Pardo et al., 2009). However, during the past
few years, it has become clear that human and mouse Gzms,
namely, GzmA, GzmM, or GzmK, are involved in processes un-
related to cytotoxicity—for example, in the regulation of the in-
flammatory response (Afonina et al., 2010; Anthony et al.,2 Cell Reports 32, 107847, July 7, 20202010b; Martı́nez-Lostao et al., 2015;Turner et al., 2019 Wensink
et al., 2015) or in processes related to their ability to degrade
extracellular matrix proteins when released in the extracellular
milieu, as reported for GzmB (Arias et al., 2017; Granville,
2010; Turner et al., 2019).
The relationship of Gzms with colon carcinogenesis is unclear.
GzmB provides cytotoxic activity against cancer cells and is a
positive prognostic marker in human CRC (Galon et al., 2012;
Pagès et al., 2005; Salama et al., 2011). By contrast, the biolog-
ical role of the other major Gzm, GzmA, during CRC is unknown.
In this study, in searching for molecules involved in inflamma-
tion during CRC, we performed transcriptomics analysis of tis-
sue samples from CRC patients and found a strong correlation
betweenGZMA expression and inflammatory genes in most mo-
lecular subtypes (consensus molecular subtypes [CMSs]). To
assess the relevance of this finding, we used the well-character-
ized dextran sodium sulfate and azoxymethane (DSS/AOM)
mouse model to demonstrate that both GzmA deficiency and
therapeutic GzmA inhibition attenuate gut inflammation and
protect mice from CRC development. Inflammation and gut
permeability in steady-state conditions were unaffected by
GzmA deficiency, confirming that reduction of inflammatory
response and CRC is not related to intestinal phenotypic
changes in the absence of GzmA. Instead, it correlated with
the ability of extracellular GzmA to induce macrophage inter-
leukin (IL) 6 production.
These results show that GzmA, acting in the extracellular envi-
ronment, regulates the inflammatory response in the gut and is a
key mediator in the development of inflammatory CRC, thus
identifying a new molecular mechanism involved in inflamma-
tion-inducedCRCand validating it as a potential new therapeutic
target. Considering that GzmA-deficient mice can control exper-
imental infections (Arias et al., 2017), our findings indicate that
targeted GzmA inhibition might be useful to prevent and treat
CRC in a more selective way than current immunosuppressive
anti-inflammatory treatments.
RESULTS
A Positive Correlation between GZMA, but Not GZMB,
and Inflammation in Human CRC Samples
An analysis of mRNA expression was performed in 98 CRC tu-
mor samples from stage 2 patients undergoing surgery (here-
after Colonomics) (Sanz-Pamplona et al., 2014). The transcrip-
tomics data were used to determine whether GZM expression
correlated with pathways involved in CRC, focusing on the two
major GZMs, GZMA and GZMB. As shown in the gene set
enrichment analysis (GSEA), GZMA was clearly co-expressed
with genes related to inflammatory pathways such as interferon
gamma (IFN-g) and interferon alpha response, IL-2, and tumor
necrosis factor alpha (TNF-a) signaling or inflammatory
response. An enrichment of genes involved in the epithelial-to-
mesenchymal transition (EMT) pathway was also detected (Fig-
ure S1B; Table S2).
Based on these encouraging results, an inflammation score
was calculated for each sample in the Colonomics dataset (Fig-
ure 1A) and in an extended dataset comprising 566 human CRC
samples (hereafter GEO: GSE39582; Figure 1B). A highly
Figure 1. GZMA Expression Positively Correlates with Inflammation Score in Human Samples Regardless of Their Molecular Subtype
(A and B) Levels of GZMA mRNA are highly correlated with inflammation score in both Colonomics (A) and GEO: GSE39582 (B) datasets. In contrast, levels of
GZMB mRNA are not correlated with the inflammation score (A and B, upper panels). The x axes indicate the intensity of GZM mRNA expression. Middle and
lower panels show correlation between GZMA expression level (x axis) and inflammation score stratified by CMS subgroup in Colonomics (A) and GEO:
GSE39582 (B) datasets. The x axes indicate GZMA mRNA expression classified according CMS groups as indicated. In all plots, Spearman’s rho correlation
value, correlation p value, and R-squared coefficients are depicted. Linear regression lines are in dashed gray.
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OPEN ACCESSsignificant positive correlation between inflammation score and
GZMA expression existed in both datasets. By contrast, no cor-
relation was observed between inflammatory score and GZMB
expression.
To evaluate whether correlation between GZMA expression
and inflammation was restricted to a specific CMS, the ana-
lyses were repeated and the samples were stratified by
CMS status in both datasets (Figures 1A and 1B, middle
and lower panels). Significant correlation was observed in all
CMS groups in both datasets, with the exception of CMS1
in Colonomics, probably because of the low number of sam-
ples. This result confirms that the presence of GZMA corre-
lates with the inflammatory status in all molecular subtypes
of colon cancer. GZMA gene expression did not correlate
with prognosis (time until tumor recurrence) in the Colonomics
cohort (data not shown). However, the Colonomics cohortonly includes stage 2 patients, who mostly recover after
surgery.
GzmA Is Elevated in Colon Tissue during CRC
Progression in Mice
To address the relevance of the findings in human samples and
to determine whether the protease plays a causal role in CRC
progression, we addressed whether attenuation of GzmA would
affect CRC development in mice. Combined administration of
DSS/AOM is awell-characterized protocol of inducing inflamma-
tory CRC inmice that mimics CRC development in humans.With
the exception of metastatic transformation, it reproduces all
stages and molecular features (mutations and EMT) of human
colorectal (CR) carcinogenesis, including aberrant crypt foci, mi-
croadenoma, adenoma, and carcinoma (DeRobertis et al., 2011;
Fichtner-Feigl et al., 2015; Takahashi et al., 1998; Yu et al., 2009).Cell Reports 32, 107847, July 7, 2020 3
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OPEN ACCESSAs shown in Figure 2A, GZMA mRNA expression was signifi-
cantly elevated in mice developing both CRC (DSS/AOM) and
chronic gut inflammation (DSS), which correlated with signifi-
cantly increased protein level in distal and proximal colonic
explant cultures from DSS/AOM- and DSS-treated wild-type
(WT)mice (Figure 2B). Notably, GzmAwas presented in superna-
tants in active form, with higher enzymatic activity in samples
from treated animals than in those from untreated WT control
mice (Figure 2C). As expected, GzmAwas not detected in super-
natants from GzmA knockout (GzmAKO) animals.
As shown in Figure 2D, the abundance of intraepithelial NK/
ILC1 cells (CD45+/NK1.1+/CD3), NKT (natural killer T) cells
(CD45+/NK1.1+/CD3+), and CD8+ T cells (CD45+/CD8a+/
CD3+) expressing GzmA was significantly increased in DSS/
AOM-treated animals. The proportion of CD8a+/CD3 cells ex-
pressing GzmA did not increase during treatment with DSS/
AOM. This population could represent resident CD8aa+/TCR/
CD3 intraepithelial lymphocytes (IELs) (Olivares-Villagómez
and Van Kaer, 2018). CD4+T lymphocytes (CD45+/CD4+/
CD3+), which did not express GzmA, increased significantly in
DSS/AOM-treated animals (Figure 2D). GzmA expression was
not detected in cells fromGzmAKO animals, confirming specificity
of detection.
CRC Development Is Reduced in GzmA-Deficient Mice
Next,wemonitoredCRCdevelopment inWTandGzmAKOanimals
macroscopically and microscopically. As shown in Figure 3A, tu-
mor incidencewas significantly higher inWTmice than inGzmAKO
mice. Furthermore, in GzmAKOmice that developed macroscopic
tumors, tumor number and size were both significantly lower than
in WT mice. The reduction of CRC development in GzmAKO mice
was similar to that observed in WT mice treated with the TNF-
a-blocking agent Enbrel (Figure S2A), which has been previously
shown to inhibit CRC development in this model (Popivanova
et al., 2008).When the experimentswere repeatedusing littermate
controls, a similar result was found. GzmAKO mice developed
fewer tumors and presented fewer clinical symptoms and less in-
testinal damage than littermate controls (Figure S3). Therefore, to
reduce the number of animals employed, inbred WT B6 animals
were used as controls for the next experiments.
As shown in Figure 3B, at the end of the experiment (56 days),
all DSS/AOM-treated WT mice presented epithelial cell transfor-Figure 2. Levels of GZMA mRNA and Active Protein Are Increased in E
GzmA by IELs
Male C57BL/6 WT mice were treated with DSS and DSS/AOM, as described in M
(A) mRNA levels of GZMA were determined by qRT-PCR (normalized to the amou
fold difference (2DDCt), as described in Method Details. Data are presented as m
one-way ANOVA test with Bonferroni’s post-test. *p < 0.05; ***p < 0.001.
(B) Colonic tissue samples (30 mg) were cultured during 24 h, supernatant was c
(C) GzmA enzymatic activity was determined. Specific activity was calculated by
animals used as control from the activity observed in WT mice. Data are presen
experiments. Statistical analyses were performed by one-way ANOVA test with
(D) IELs were isolated fromWT and GzmAKO mice at day 49 of treatment with DSS
CD3-FITC, anti-CD8a-APC, anti-NK1.1-APC-Vio770, and anti-CD45-VioBlue a
antibody. A representative experiment is shown. Numbers in dot plots represe
untreated WT and GzmAKO mice were isolated as control. Data in bar graphs repr
the percentage of each subtype of IELs isolated from treated and untreated W
performed by Student’s t test, comparing treated WT mice with untreated WT mmation, although at different stages (Figure S4A). Adenocarci-
noma was present in 50%, and dysplasia of low and high degree
was present in 30% and 20%, respectively. By contrast, 20% of
GzmAKO mice showed no CRC or dysplasia and only 20% pro-
gressed to adenocarcinoma. Similar differences were observed
at early time points after initiating DSS/AOM treatment. At day
47, 40% of GzmAKO mice did not present any type of tumor
and the rest only presented dysplasia. In contrast, all WT mice
presented dysplasia and 13% presented carcinoma. At day 28,
dysplasia was observed in only 37% of GzmAKO mice, but it
was already evident in 60% of WT mice. These results confirm
that GzmA plays a critical role in development of CRC and likely
in the perpetuation of the cancerous state.
Similar results were obtained when we analyzed proliferation
(Ki-67) and EMT (vimentin, b-catenin, and SNAIL-1) markers by
immunohistochemistry, confirming the critical role of GzmA in
epithelial cell transformation and CRC development (Figures
3C and 3D; Figure S4B). Analyses were performed at day 28
(4 weeks) of DSS/AOM treatment, after which EMT begins (De
Robertis et al., 2011; Takahashi et al., 1998). Vimentin was ex-
pressed in a large number of cells, especially in the areas of
dysplasia of WT animals treated with DSS/AOM. The absence
of GzmA significantly reduced the number of vimentin-positive
cells in the mucosa and submucosa layers. Similarly, DSS/
AOM-exposed animals showed a significant increase in cyto-
plasmic and nuclear b-catenin in epithelial cells, whereas
GzmAKO animals showed b-catenin staining restricted mostly
to the cell membrane. SNAIL-1 expression was also increased
in DSS/AOM-treated mice, showing high positivity in the lamina
propria and the connective tissue. In GzmAKO mice, the staining
pattern was similar to that in untreated control mice (Figure S4B),
with few positive cells in the connective tissue.
Finally, an increase in the number of proliferative cells could be
seen with the Ki-67 marker. In DSS/AOM-treatedWT animals, the
positivitywas not restricted to the basal area of the colonic glands,
but it reached the vicinity of the apical zone in certain cases. In
contrast, DSS/AOM-treatedGzmAKO animals showed thismarker
restricted to the basal area, similar to the untreated control ani-
mals (Figure S4B). The expression of all markers in untreated
GzmAKO andWTcontrol animals was similar (Figure S4B). The dif-
ferences between WT and GzmAKO animals were statistically sig-
nificant in all cases (Figure 3D). Strong Ki-67, vimentin, andxplants from DSS- and DSS/AOM-Treated Mice, with Expression of
ethod Details, and sacrificed at day 56.
nt of HPRTmRNA). The relative gene expression levels were expressed as the
ean ± SEM from 3 biological replicates. Statistical analyses were performed by
ollected, and GzmA was quantified by ELISA in proximal and distal colon.
subtracting the residual unspecific tryptase-like activity detected in GzmAKO
ted as mean ± SEM from 5 biological replicates performed in 3 independent
Bonferroni’s post-test. *p < 0.05; ***p < 0.001.
/AOM, as indicated in Method Details, and stained with a combination of anti-
ntibodies. Intracellular GzmA expression was analyzed using anti-GzmA-PE
nt the percentage of GzmA-positive cells for each IEL phenotype. IELs from
esent the mean ± SEM of GzmA-positive cells of each IEL phenotype (left) and
T mice (right) from two independent experiments. Statistical analyses were
ice. *p < 0.05.
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Figure 3. CR Carcinoma Development in DSS/AOM-Treated Mice
CRC was induced in male C57BL/6 WT and GzmAKO mice with DSS and AOM, as described in STAR Methods.
(A) Number of animals bearing tumors (tumor incidence), tumor diameter, and number of tumors per animal were evaluated. Data are presented asmean ±SEMof
31 (WT) and 24 (GzmAKO) biological replicates (individual mice) in 4 independent experiments. Statistical analyses were performed by one-way ANOVA test with
Bonferroni’s post-test. *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Colonic tissues were removed and processed for histopathology. Representative microphotographs of H&E-stained colonic sections show low-grade
dysplasia (a), high-grade dysplasia (b), and carcinoma (c). Scale bars, 100 mm. Histologic tumor grade was established in WT and GzmAKOmice and represented
as the percentage of mice with the indicated tumor grade (highest tumor grade found) within each group.
(legend continued on next page)






OPEN ACCESSSNAIL-1 positivity was observed in connective-tissue-associated
fibroblast-like cells only in DSS/AOM-treatedWTmice, which is in
line with the changes observed in connective tissue before EMT
occurs (Kalluri and Weinberg, 2009).
Inflammation Is Reduced in Colon Tissue from GzmA-
Deficient Mice during CRC Development
It is well known that during DSS/AOM-induced CRC, tumors
almost exclusively appear in the distal part of the colon. Thus,
to test the effect of GzmA deficiency on intestinal inflammation
independent of tumor development, the production of proinflam-
matory cytokines was analyzed in both proximal and distal
colonic tissue. This is important, because once tumors develop,
the inflammatory reaction is downregulated in tumoral tissue,
which might mask the potential contribution of GzmA to intesti-
nal inflammation and CRC. Indeed, as shown in Figure 4A, levels
of proinflammatory cytokines (IL-1b, TNF-a, IFN-g, IL-6, and IL-
17) were higher in proximal colon compared with distal colon. In
proximal colon, all proinflammatory cytokines tested were signif-
icantly higher in WT animals than in GzmAKO mice. In distal co-
lon, proinflammatory cytokines were also significantly higher in
DSS/AOM-treated WT mice than in untreated WT B6 mice,
although in this case differences between WT and GzmAKO ani-
mals were only significant for TNF-a, IFN-g, and IL-6. However,
IL-10, an anti-inflammatory cytokine involved in maintaining in-
testinal homeostasis (Glocker et al., 2011; K€uhn et al., 1993),
was significantly lower in WT mice than in GzmAKO mice in
both proximal and distal colon. In contrast to WT mice, only IL-
17 was significantly increased in DSS/AOM-treated GzmAKO an-
imals relative to untreated controls.
As shown in Figure 4B, COX-2 mRNA expression and PGE2
production were significantly higher in WT mice compared with
untreated controls and comparedwithGzmAKOmice, confirming
that COX-2 activity was reduced in the absence of GzmA.
The contribution of inflammatory cytokines and PGE2 to CR
carcinogenesis is critically modulated by the transcription factor
STAT3, which is activated upon phosphorylation. As shown in
Figure 4C, pSTAT3 was induced in cells of the mucosa and sub-
mucosa of DSS/AOM-treated animals, with many positive cells
in the areas of dysplasia. A significant decrease in positivity
was observed in the GzmAKO group treated with DSS/AOM, in
comparison withWTmice, although the number of pSTAT3-pos-
itive cells remained higher than in untreated animals (Figure S4B).
Thus, protection against CRC development granted by GzmA
deficiency consistently correlates with reduction in the carcino-
genic proinflammatory state in gut.
Analyses of gut microbiota in both WT and GzmAKO mice, em-
ploying 16S rDNA sequencing, revealed that both mouse strains
present an almost identical composition of bacterial gut micro-
biota at the genus level (Figure S5), thus ruling out differences
in the composition of the gut microbiome as a factor modulating
the increased resistance of GzmAKO mice to inflammatory CRC(C) Group of DSS/AOM-treatedmicewere sacrificed at day 28, and colon tissue se
Scale bars, 100 mm.
(D) Graphs representing the percentage of Ki-67-positive nuclei and the number o
were performed by quantifying all cells in five random fields per tissue slide (3 slid
SEM from at least 5 biological replicates (individual mice). Statistical analyses wdevelopment. This finding is not unexpected, because indepen-
dent recent studies indicate that mice hosted at the same animal
facility contain identical microbiota due to the same feed and
environmental stress conditions (Ericsson et al., 2018; Montonye
et al., 2018).
Gut Inflammation Is Attenuated in GzmA-Deficient (KO)
Mice
To address whether GzmA also regulates the gut inflammatory
response in the absence of CRC, we induced DSS colitis without
AOM. As shown in Figure 5A, WT mice displayed a pronounced
reduction of body weight in the first week after DSS treatment.
Weight loss was significantly attenuated in GzmAKO mice (Fig-
ure 5A). The severity of colitis in GzmAKO mice was also signifi-
cantly decreased compared with WT mice, as indicated by the
clinical score (Figure 5A). Attenuated weight loss and reduced
clinical regression resulted in a significant increase in survival
of GzmAKO mice relative to WT mice (Figure 5B). During DSS-
induced colitis, most WT mice died during the acute phase;
thus, later on, the differences between WT and GzmAKO were
less pronounced in terms of clinical score and weight loss. In
addition, once animals entered the chronic phase, the disease
severity was reduced macroscopically (score and weight);
thus, the differences were attenuated.
Next, we analyzed the pathological changes observed in colon
tissue during DSS-induced colitis and compared these with
DSS/AOM-treated animals. As shown in Figure 5C, we found
significant shortening in colon length and increased wet weight
inWTmice relative to GzmAKOmice. Both colon length reduction
and weight increase are common changes observed during co-
litis. The inflammatory macroscopic score was significantly
lower in GzmAKOmice than inWTmice. Histological microscopic
examination (Figure 5D) was consistent with the macroscopic
colitis and clinical score. DSS-treated WT mice showed leuko-
cyte infiltration in the lamina propria, epithelial hyperplasia, and
the presence of markers of severe inflammation, such as crypt
abscesses, submucosal inflammation, and ulcers. By contrast,
GzmAKO mice showed fewer signs of inflammation and mucosal
injury. The inflammatory infiltrate in the colon of GzmAKO mice
only affected superficial layers of the mucosa, whereas the
crypts weremore preserved. Individual parameters and total his-
tological score (the sum of all individual parameters) were both
significantly lower in GzmAKO mice than in WT mice.
Similar results were found in DSS/AOM-treated mice,
although in this case, the severity and disease scores are
reduced in comparison with DSS-treated animals (Figure S6).
Inflammatory Cytokines Are Reduced in Gut from
GzmAKO Mice during Acute and Chronic Inflammation
A role for GzmA in gut inflammation was confirmed when
analyzing the generation of proinflammatory cytokines in CR tis-
sue from DSS-treated animals. In acute colitis (Figure S7A), allctions were stainedwith antibodies to vimentin, b-catenin, SNAIL-1, and Ki-67.
f positive cells per field for SNAIL-1 and vimentin among all crypt cells. Analyses
es per animal), as indicated in STAR Methods. Data are presented as mean ±
ere performed by unpaired t test. *p < 0.05; ***p < 0.001.
Cell Reports 32, 107847, July 7, 2020 7
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OPEN ACCESScytokines tested were significantly increased in WT animals
compared with GzmAKO mice, in both proximal and distal colon,
except for IL-6. As expected, we found lower levels of IL-10 in
DSS-treated animals compared with untreated healthy animals,
without significant differences between WT and KO strains.
However, IL-10 levels were slightly higher in GzmAKO than in
WT mice during DSS-induced colitis. The level of IL-10 was
only significantly reduced by DSS treatment in proximal colon
tissue from WT mice.
During chronic colitis, all inflammatory cytokines were also
significantly reduced in GzmAKO mice relative to WT mice in
both proximal and distal colon (Figure S7B). None of the cyto-
kines significantly increased in DSS-treated GzmAKO mice. In
contrast to proinflammatory cytokines, the level of IL-10 was
significantly decreased in WT mice compared with GzmAKO
mice, in both proximal and distal colon.
The steady-state level of inflammatory cytokines in untreated
mice (Figure 4A; Figure S7) is similar in WT and GzmAKO groups,
indicating that basal differences in colon integrity do not
contribute to the attenuation of inflammation and CRC develop-
ment in GzmAKO mice. Confirming this assumption, baseline in-
testinal permeability was not different between WT and GzmAKO
mice (Figure S2C).
Altogether, the results employing the intestinal inflammatory
model confirm the role of GzmA in modulating gut inflammation
and CRC development in vivo.
Extracellular GzmA Induces IL-6 Production in M1
Macrophages by NF-kB, which Is Not Affected by COX-2
or Inflammasome Inhibition
As shown earlier, several proinflammatory cytokines were signifi-
cantly reduced inGzmAKOanimals in comparisonwithWTanimals
during CRC and colitis in vivo (Figure 4A; Figure S7). In addition,
active GzmA was present in supernatants from ex vivo colon cul-
tures. Thus,weaddressedwhether extracellularGzmAcan induce
theproductionofproinflammatorycytokines inprimaryM1macro-
phages, focusing in those known to be produced by this cell type:
IL-6, TNF-a, and IL-1b. Asshown inFigureS2E,GzmAsignificantly
induced the expression of IL-6 and TNF-a in macrophages. In
contrast, IL-1b was not induced by GzmA. Lipopolysaccharide
(LPS) significantlyenhanced thegenerationofall cytokines.Our re-
sults suggest thatGzmA isable to inducean inflammatorycytokine
response in vitro with a specific increase in IL-6 and TNF-a.
Because of the complexity of the networks involved in cytokineFigure 4. GzmA Deficiency Attenuates Colon Inflammation during CRC
CRC was induced in male C57BL/6 WT and GzmAKO mice, as described in STAR
cultured during 24 h.
(A) Supernatant was collected and the levels of IL-1b, TNF-a, IFN-g, IL-6, IL-17
presented as mean ± SEM from at least 10 biological replicates performed in 4
ANOVA test with Bonferroni’s post-test. *p < 0.05; **p < 0.01; ***p < 0.001.
(B) mRNA levels of COX-2 were determined by qRT-PCR (normalized to the am
replicates (individual mice) performed in 2 independent experiments. Statistical
quantified by ELISA in ex vivo culture of colonic tissue. Data are presented as me
independent experiments. Statistical analyses were performed by one-way ANO
(C) Group of mice were sacrificed at day 28, and colon tissue sections were stai
number of positive cells per field for pSTAT3 among all crypt cells. Analyses were
per animal), as indicated in STAR Methods. Data are presented as mean ± SEM
performed by unpaired t test. *p < 0.05.expression and specially in the context of in vivo inflammatory re-
sponses, we focused our efforts to analyze the mechanism
involved in IL-6 production, a cytokine that plays a key negative
role in the regulation of CRC development in both humans and
mice.
As shown in Figure 6A, GzmA-mediated induction of IL-6 was
markedly reduced in the presence of the GzmA-specific inhibitor
serpinb6b (Kaiserman et al., 2014) and was not reproduced with
inactivated GzmA, confirming that GzmA induces IL-6 produc-
tion by a mechanism involving proteolysis.
As shown in Figure 6B, the specific NF-kB inhibitor celastrol
abrogated IL-6 production mediated by GzmA. As expected, ce-
lastrol also inhibited IL-6 production induced by LPS, confirming
the efficacy of the inhibitor to block NF-kB-dependent cytokine
production. In contrast, IL-6 production was not affected by
the COX-2 inhibitor celecoxib or the caspase-1 inhibitor VX-
765 (Figure 6B), suggesting that the regulation of IL-6 by GzmA
during DSS/AOM-induced tumorigenesis is independent of
COX-2 and inflammasome/caspase-1 activity. Extracellular
GzmA did not affect macrophage viability (Figure 6C), suggest-
ing that generation of IL-6 was not a consequence of the release
of cell debris or other molecules as a consequence of macro-
phage cell death.
IL-6 production in response to GzmA was undiminished in
macrophages deficient in either protease-activated receptor 1
(PAR1) or PAR2 (Figure S2F). Thus, these results do not support
for a role of these receptors during GzmA-mediated inflamma-
tion in macrophages.
Next, we determined whether the IL-6 induced by GzmA in
macrophages promotes the activation of pSTAT3 in the MC-
38 cell line (Figure 6D). As expected, IL-6 increased the expres-
sion of pSTAT3 that was inhibited by a blocking anti-IL-6 anti-
body. Similarly, the stimulation of MC-38 cells with supernatant
of macrophages previously stimulated with recombinant mouse
GzmA increased the phosphorylation of STAT3, which was pre-
vented by blocking IL-6. Stimulation of MC-38 with superna-
tants from macrophages stimulated with LPS, a potent IL-6
inductor, also increased the expression of pSTAT3 (Figure 6D).
Direct stimulation of MC-38 cells with recombinant mouse
GzmA did not increase the expression of pSTAT3 (Figure 6D;
Figure S2D). These results argue that reduced pSTAT3 in
colonic tissue from GzmA-deficient DSS/AOM-treated mice
(Figure 4C) is secondary to the reduction in IL-6 production in
these mice.Development Induced by DSS/AOM
Methods, which were sacrificed at day 56 with colonic tissue samples (30 mg)
, and IL-10 were quantified by ELISA in proximal and distal colon. Data are
independent experiments. Statistical analyses were performed by one-way
ount of HPRT mRNA). Data are presented as mean ± SEM from 4 biological
analyses were performed by unpaired t test. *p < 0.05. Levels of PGE2 were
an ± SEM from at least 10 biological replicates (individual mice) performed in 4
VA test with Bonferroni’s post-test. **p < 0.01.
ned with antibodies to pSTAT3. Scale bars, 100 mm. The graph represents the
performed by quantifying all cells in five random fields per tissue slide (3 slides
from at least 5 biological replicates (individual mice). Statistical analyses were
Cell Reports 32, 107847, July 7, 2020 9
Figure 5. DSS-Induced Colitis and Macroscopic and Microscopic Damage Are Attenuated in GzmA-Deficient Mice
Male C57BL/6 WT and GzmAKO mice were treated with DSS, as described in STAR Methods.
(A) Changes in weight and clinical score were evaluated every 1–2 days. Data are presented as mean ± SEM of 33 (WT) and 26 (GzmAKO) biological replicates
(individual mice) performed in 4 independent experiments. Statistical analyses were performed by two-way ANOVA test with Bonferroni’s post-test. *p < 0.05;
**p < 0.01; ***p < 0.001.
(B) Survival curves corresponding to 33 (WT) and 26 (GzmAKO) biological replicates (individual mice) performed in 4 independent experiments. Statistical analyses
were performed by log rank test. *p < 0.05.
(C) At the end of the study, the animals were sacrificed, the colon was measured and weighed, and the visible colon damage was scored, as described in STAR
Methods. Data are presented as mean ± SEM of 33 (WT) and 26 (GzmAKO) biological replicates (individual mice) in 4 independent experiments. Statistical an-
alyses were performed by one-way ANOVA test with Bonferroni’s post-test. **p < 0.01; ***p < 0.001.
(D) Colonic tissues were removed and processed for histopathology, as described in Method Details. Representative pictures are shown in the left panels. Scale
bar, 100 mm. Asterisks indicate inflammation, and arrows show hypertrophic lymphatic vessels in DSS-treated mice. A histological score was established, as
indicated in Method Details. The right graph represents the score of each parameter and the total score. Data are presented as mean ± SEM of 5 (WT and
GzmAKO) biological replicates (individual mice). Statistical analyses were performed by one-way ANOVA test with Bonferroni’s post-test. *p < 0.05; **p < 0.01.
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OPEN ACCESSTherapeutic GzmA Inhibition Reduces CRC
Development
Finally, we decided to evaluate whether therapeutic inhibition
of GzmA in WT mice with established gut inflammation would
attenuate inflammation and prevent CRC progression. Thus,
WT mice were treated with the inhibitor serpinb6b 35 days af-
ter DSS/AOM treatment, when the intestinal barrier was
already disrupted and EMT and colon dysplasia were initiated.
As shown in Figure 7A, the levels of IL-6 and TNF-a in super-
natants from explant cultures was significantly reduced in WT10 Cell Reports 32, 107847, July 7, 2020mice treated with serpinb6b in both distal and proximal colon,
suggesting that extracellular GzmA drives inflammation in
DSS/AOM-treated animals. No reduction was observed with
an inactive serpinb6b. The reduction in macroscopic colon
damage obtained with serpinb6b treatment was similar to
that observed with genetic GzmA deficiency (Figure 7B).
Notably, serpinb6b treatment also significantly reduced the
incidence and the number of tumors in DSS/AOM-treated
WT mice (Figure 7B), confirming that therapeutic inhibition of
extracellular GzmA reduces inflammatory CRC.
Figure 6. Extracellular GzmA Induces IL-6 Production by Macrophages and Promotes Activation of STAT3
(A) Bone-marrow-derived M1macrophages were stimulated with active GzmA (300 nM) or GzmA inactivated with serpinb6b, a specific inhibitor of mouse GzmA.
(B) Macrophages were treated with specific inhibitors of NF-kB (celastrol), COX-2 (celecoxib), or caspase-1 (VX-765) during the 1 h before the addition of GzmA
(300 nM). As positive control, macrophages were stimulated with E. coli LPS (100 ng/mL). Macrophages were incubated for 24 h at 37C and 5% CO2, su-
pernatants were collected, and the levels of IL-6 were measured by ELISA. Data are presented as mean ± SEM from two independent experiments performed by
triplicates. Statistical analyses were performed by one-way ANOVA test with Bonferroni’s post-test. *p < 0.05; ***p < 0.001.
(C) PrestoBlue cell viability of macrophages stimulated with active GzmA (300 nM), GzmA inactivated with serpinb6b, 100 ng/mL E. coli LPS, or 100 ng/mL E. coli
LPS with 5 mM ATP for 24 h.
(D) Western blot of MC-38 cells incubated with mouse IL-6 (50 ng/mL) (as positive control), supernatant from recombinant mouse GzmA-stimulated macrophage
(300 nM), or supernatant from LPS-stimulated macrophage (100 ng/mL). Supernatant from unstimulated macrophage, supernatant from recombinant mouse
GzmA-stimulated macrophage treated with mAb IL-6 or isotype (BioXCell), and supernatant from mouse IL-6 treated with mAb IL-6 or isotype (BioXCell) were
added as control. The cells were stimulatedwith the indicated stimuli for 15min, after which cells were lysed andwestern blotted using pSTAT3 antibody (Tyr705).
IL-6-dependent changes in STAT3 phosphorylation were evaluated by quantifying band intensities on pSTAT3 blots and comparing to b-actin band intensities as




If not properly regulated, inflammatory mechanisms involved in
host defense and cancer immunosurveillance can promote can-
cer development, progression, and resistance to treatment. The
best example of this dichotomy is CRC (Crusz and Balkwill,2015; Erreni et al., 2011; Shalapour and Karin, 2015), the sec-
ond-most deadly of all cancers. Here we identify extracellular
GzmA as a new mechanism by which the immune system can
facilitate CRC development, thus contributing to understanding
of the molecular mechanism underlying this pathology and
opening a new therapeutic opportunity.Cell Reports 32, 107847, July 7, 2020 11
Figure 7. A Macromolecular GzmA Inhibitor Reduces CRC and Colon Inflammation in DSS/AOM-Treated WT Mice
CRC was induced in male C57BL/6 WT and GzmAKO mice with AOM, as described in STAR Methods. On day 35, a group of mice was treated with five doses of
serpinb6b (20 mg intravenously [i.v.]) every other day. Mice were sacrificed at day 50. As control, a group of mice was treated with inactivated serpinb6b.
(A) Colonic tissue samples (30 mg) were cultured during 24 h, supernatant was collected, and the levels of IL-6 and TNF-a were quantified by ELISA in proximal
and distal colon.
(B) Macroscopic colon damage score, number of tumors, and incidence of tumors. Data are presented as mean ± SEM from at least 10 biological replicates
(individual mice) performed in 3 independent experiments. Statistical analyses were performed by one-way ANOVA test with Bonferroni’s post-test. *p < 0.05;
**p < 0.01; ***p < 0.001.
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OPEN ACCESSGzmA belongs to a family of serine proteases traditionally
recognized as anti-tumor and anti-infective agents because of
the ability to trigger cell death on target cells in vitro. Challenging
this dogma, we now show that GzmA plays a critical role in pro-
moting gut inflammation and thereby tumor development. This
effect correlates with the ability of extracellular GzmA to promote
NF-kB-dependent IL-6 production in macrophages, which in
turn, results in IL-6-dependent pSTAT3 activation in CRC cells.
Although several inflammatory molecules have been shown to
modulate the different stages of epithelial cell transformation
and CRC development, our combined in vitro and in vivo data
indicate that GzmA-induced IL-6 production may provide an
important link between immune cell infiltration and activation of
STAT3 and other protumorigenic pathways duringCRCdevelop-
ment. This does not exclude that other mechanisms could link
GzmA to inflammation and CRC development, such as modula-
tion of intestinal permeability or proteolytic release of inflamma-
tory damage-associatedmolecular patterns (DAMPs) from intes-
tinal cells. GzmB has been reported to release peptides with
proinflammatory activity derived from the extracellular matrix
(Turner et al., 2019).
The data showing that therapeutic inhibition of GzmA by ser-
pinb6b represent a proof of concept that GzmA is a potential
therapeutic target in CRC. These results are not directly translat-
able, because serpinb6b does not block human GzmA. Anti-
thrombin III (SerpinC1) is an endogenous inhibitor of human
GzmA (Masson and Tschopp, 1988) that is reduced during12 Cell Reports 32, 107847, July 7, 2020CRC (Peltier et al., 2016). Supporting the translational relevance
of our findings, our analysis of human CRC patients shows
strong correlation between GZMA expression and inflammatory
score.
Importantly, the conclusions arising from study of GzmA-
deficient animals were confirmed by employing an extracel-
lular GzmA inhibitor in WT mice, negating the argument that
protection is related to the presence of an existing colonic
phenotype in GzmAKO animals at baseline that might be
driving a DSS-protective phenotype. Strengthening this
conclusion, we show that microbiota composition, inflamma-
tory cytokine levels, and intestinal permeability at steady state
are identical in WT and in GzmAKO mice. Moreover, the extra-
cellular GzmA inhibitor, serpinb6b, was effective when inocu-
lated at 5 weeks, indicating that the loss of intestinal barrier
during DSS/AOM treatment can be dissociated from the effect
of GzmA on CRC development. GzmA is the first member of
the Gzms family shown to promote gut inflammation and
CRC development. GzmM has been reported to protect
against colitis and CRC in the DSS/AOM model (Souza-Fon-
seca-Guimaraes et al., 2016), suggesting that therapeutic
approaches would need to be specific for GzmA. We did not
find significant expression of GZMM in transcriptomics anal-
ysis of two cohorts of human CRC samples (data not shown).
GZMK and GZMH expression also correlated with inflamma-




OPEN ACCESSThe role of inflammation has been widely studied during tumor
development, although the molecular mechanisms involved
have not been completely elucidated. Thus, until now, the bal-
ance between beneficial and deleterious effects of inflammation
(host protection versus tumor development/progression) has not
been well understood. Most molecules identified as protumor in-
flammatory factors are also critically involved in protection, with
the notable exception of COX-2. Thus, manipulation of inflam-
mation is difficult to achieve during cancer treatment without
risking adverse effects, including opportunistic infections
(Rose-John et al., 2017; Salvana and Salata, 2009). Previous re-
sults from us and others have shown that GzmAKO mice effi-
ciently clear experimental viral and bacterial infections, as well
as tumors (Anthony et al., 2010a; Arias et al., 2014; Trapani
and Smyth, 2002). Thus, GzmA inactivation should not predis-
pose a patient to major side effects including infection and can-
cer, unlike other common anti-inflammatory drugs, like IL-6 or
TNF-a blockers (Rose-John et al., 2017; Salvana and Salata,
2009).
Our study has identified GzmA as a potential target to treat
CRC, and our data suggest that its potential effects are mainly
mediated at the extracellular level. The cellular sources respon-
sible for GzmA secretion and CRC development remain to be
defined. High levels of infiltrating lymphocytes expressing
GzmA have been previously found in humans with UC (M€uller
et al., 1998), and patients expressing high levels of GZMA in
CD4+integrin-aE+ cells had a better response to anti-inflamma-
tory immunotherapy with a monoclonal antibody (mAb) against
the b7-integrin subunit (etrolizumab) (Tew et al., 2016). Reflecting
the situation in UC patients, we have found that conventional
CD8+/CD3+ T cells, CD8aa+ lymphocytes, and NK/ILC1 cells in-
crease in the intestinal tissue of mice treated with DSS/AOM.
However, in contrast to the previously mentioned studies,
GzmA expression was mainly associated with CD8+ lympho-
cytes, NK cells, and NKT cells, but not with CD4+ T cells, indi-
cating that the mechanism by which GzmA contributes to UC
and CRC might be different. It is plausible that some of these
cells could secrete GzmA after activation of specific pattern
recognition receptors (PRRs) in response to extracellular
microbe-derived components present in the colon (reviewed in
Souza-Fonseca-Guimaraes et al., 2012). This hypothesis will
be difficult to test, because depletion of NK/NKT or CD8+ cells
would be expected to modulate tumor progression independent
of GzmA. There have been no previous studies investigating
GzmA expression in CRC patients. In agreement with the results
in the mouse model, we have found a clear correlation between
GZMA and inflammation in two independent datasets
comprising human tumors with different clinical and molecular
characteristics. No such correlation exists between GZMB and
inflammation. Although this does not necessarily imply a causal
role of GZMA expression in inflammation, the combined results
in mouse and human models strongly suggest a role for GzmA
in regulating inflammation during CRC. We also analyzed
whether GzmA could have a prognostic value in CRC patients
but did not find correlation betweenGZMA expression and prog-
nosis (measured as time to recurrence or overall survival) in our
Colonomics database or in larger public databases (GEO:
GSE39582 or the Human Protein Atlas). These results suggestthat GzmA would have a prominent role in the first stages of
CR carcinogenesis, but once macroscopic tumors have been
developed, other molecules would be more relevant for cancer
progression. Supporting this hypothesis, other factors known
to critically contribute to CRC development, such IL-6 or Cox-
2, did not show prognostic value in the databases indicated
earlier, suggesting that like GzmA, these molecules might
contribute to cancer initiation, rather than progression. Indeed,
recent data indicate that Th1-related inflammation in human can-
cer, including CRC, is a protective factor once tumors are estab-
lished, suggesting that the detrimental effects of inflammation
during tumor initiation might have opposing role once tumors
are established (Ponzetta et al., 2019).
A key to understanding the carcinogenicmechanism activated
by GzmA, and hence to therapeutically targeting this enzyme, is
the location of its proinflammatory action—specifically, whether
GzmA-induced inflammation requires intracellular delivery by
perforin or whether it can be triggered from the extracellular
space. We showed that active GzmA is present in the superna-
tant of colon explant cultures ex vivo and that in vivo inactivation
of GzmA by exogenous serpinb6b reduces inflammation and
CRC incidence. We additionally showed that extracellular active
GzmA induces the expression of IL-6 in M1macrophages, which
have been linked to CRC in humans (Shabo et al., 2014) and
DSS/AOM-treated mice (Wang et al., 2015), in a process in-
hibited by NF-kB inactivation. Supporting our data in mice, we
have previously found that extracellular active GzmA induces
the generation of IL-6 in non-primed human macrophages (Met-
kar et al., 2008), although the mechanisms underlying this pro-
cess are unknown. Thus, all our results support that GzmA exerts
its proinflammatory carcinogenic function from the extracellular
space, a key finding to design therapeutic approaches to block
GzmA activity. In summary, GzmA constitutes a new molecular
mechanism that contributes to CRC development in vivo by
regulating gut inflammatory responses using mechanisms that
sustain the perpetuation of an inflammatory microenvironment,
probably by its action on tissue macrophages. Therapeutic inhi-
bition of extracellular GzmA reduces inflammation and tumor
number and incidence, suggesting that the development of
effective GzmA inhibitors could have a beneficial effect in the
treatment of gut inflammation and CRC development in a more
selective and safer way than other therapies commonly used in
the treatment of these diseases.STAR+METHODS
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Antibodies
Anti-p-STAT3 (Tyr705) (Rabbit anti-mouse) Cell Signaling Cat# 9145S
Anti-p-NF-kB p65 (Ser536) (Rabbit anti-mouse) Cell Signaling Cat# 3000S
Anti-IkBa (44D4) (Rabbit anti-mouse) Cell Signaling Cat# 4812S
Anti-b-Actin (mouse monoclonal) Sigma Cat#A5316
Anti-a-tubulin Sigma Cat# T5168
IRDye 800CW goat anti-Rabbit IgG Li-Cor Cat# 926-32211
IRDye 680RD goat anti-Mouse IgG Li-Cor Cat# 926-68070
FITC anti mouse CD3 Miltenyi Biotec Cat# 130-119-758
PE anti mouse GzmA BioLegend Cat# 149703
PE mouse IgG2b BioLegend Cat# 400311
APC anti mouse CD8a Miltenyi Biotec Cat# 130-120-159
APC anti mouse CD4 Miltenyi Biotec Cat# 130-116-526
APC-Vio770 anti mouse NK1.1 Miltenyi Biotec Cat# 130-120-510
VioBlue anti mouse CD45 Miltenyi Biotec Cat# 130-110-664
Chemicals, Peptides, and Recombinant Proteins
Dextran Sulfate Sodium, Colitis grade 36.000–50.000 MP Biomedicals Cat# 9011-18-1
Azoxymethane (AOM) Sigma-Aldrich Cat# A5486
FITC-Dextran Sigma Cat# FD4-100MG
Dulbecco’s modified Eagle’s medium (DMEM) Sigma Cat# 5796
Penicillin-Streptomycin (10.000 U/10 mg/ml) Sigma Cat# P4333
Fetal bovine serum (FBS) Sigma Cat# F2442
Trypsin-EDTA (0.25%), phenol red Sigma Cat# T4049-100ML
HBSS without Mg2+ and Ca2+ Sigma Cat# H6648-500ML
HEPES solution 1M Sigma Cat# H0887-20ML
2-mercaptoethanol Sigma Cat# M7522
Percoll Sigma Cat# P1644-100ML
Dithiothreiteol (DTT) Sigma Cat# 3383-12-3
Recombinant mouse GzmA This paper N/A
Recombinant mouse Serpinb6b This paper N/A
Cathepsin C Sigma Cat# 9032-68-2
Enbrel (Etanercept) Gift from Dra. Ana Marı́a
Ortiz Garcı́a (La Princesa
University Hospital, Madrid, Spain)
N/A
Bz-Pro-Phe-Arg-pNA.HCl Bachem Cat# 4012267
Critical Commercial Assays
Mouse IL-1b ELISA Ready set Go! Kit eBioscience Cat# 88-7013-88
Mouse IL-6 ELISA Ready set Go! Kit eBioscience Cat# 88-7064-77
Mouse IL-10 ELISA Ready set Go! Kit eBioscience Cat# 88-7105-76
Mouse IL-17A ELISA Ready set Go! Kit eBioscience Cat# 88-7371-77
Mouse IFNg ELISA Ready set Go! Kit eBioscience Cat# 88-73-84-21
Mouse TNFa ELISA Ready set Go! Kit
Ready set Go! Kit
eBioscience Cat# 88-7324-86
Mouse PGE2 ELISA Kit Arbor Assay Cat# K051-H1
RNeasy Mini Kit QIAGEN Cat# 74104
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SYBRTM Green PCR Master Mix Applied Biosystems Cat# 4309155
SuperScriptTM II Reverse Transcriptase Invitrogen Cat# 18064014
Deposited Data
16S rDNA sequencing data This paper https://www.ncbi.nlm.nih.gov/
sra/PRJNA634245
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GZMA forward 50-GGTGGAAAGGACTCCTGCAA-30 ThermoFisher N/A
GZMA reverse 50-GCCTCGCAAAATACCATCACA-30 ThermoFisher N/A
COX-2 forward 50-TGCCTCCCACTCCAGACTAGA-30 ThermoFisher N/A
COX-2 reverse 50-CAGCTCAGTTGAACGCCTTTT-30 ThermoFisher N/A
HPRT forward 50-CTGGTGAAAAGGACCTCTCGAA-30 ThermoFisher N/A









GraphPad Prism 5 Graphpad Software N/A
ImageJ (Schneider et al., 2012) https://imagej.nih.gov/ij





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Julián
Pardo (pardojim@unizar.es)
Materials Availability
Recombinant mouse Granzyme A generated in this study is available from the Lead Contact without restriction.
Data and Code Availability
The 16S rDNA sequencing data generated during this study is available at https://www.ncbi.nlm.nih.gov/sra/PRJNA634245.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human samples
Gene expression data from a set of 98 tumor tissues fromCRCpatients was used (Colonomics project: https://www.colonomics.org,
NCBI BioProject PRJNA188519). Briefly, RNA extracted from each sample was hybridized in Affymetrix chips Human Genome U219
and analyzed under standard protocol (Sanz-Pamplona et al., 2014). Both raw and normalized data are available in the Gene Expres-
sion Omnibus (GEO) database through accession number GSE44076. All patients were stage II, MSS, treated with radical surgery
and did not received adjuvant chemotherapy. They were recruited at the Bellvitge University Hospital (Spain) between 1998 ande2 Cell Reports 32, 107847, July 7, 2020
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OPEN ACCESS2002, provided written informed consent and the hospital Ethics Committee approved the protocol with reference PR074/11. Pa-
tients’ characteristics are summarized in Table S1.
Mice
Inbred C57BL/6 (Wt), and mouse strains deficient (knockout/KO) for granzyme A (GzmAKO/GzmA/) on the B6 background were
bred and maintained at the CIBA (Centro de Investigación Biomédica de Aragón; SCT Animal Facility). Their genotypes were peri-
odically analyzed as described (Pardo et al., 2008). Animal experimentation was approved by the Ethics Committee for Animal Exper-
imentation from University of Zaragoza (protocol number PI17/15). Male 8-10-week-old mice were used for all experiments. To con-
trol that the differences between Wt and GzmAKO animals were not affected by minor differences in genetical backgrounds and/or
other factors control littermates were employed in some experiments.
Cells lines and primary cell cultures
Primary M1 macrophages were differentiated from bone marrow of C57BL/6 mice. Cells were aseptically collected from bone
marrow and resuspended in RPMI 1640 medium containing 10 % of FCS serum, 100 U/ml of penicillin/streptomycin, 50 mM of 2-
ME, and 10 % of supernatant of X63Ag8653 cell cultures as source of GM-CSF (74) (GM-CSF medium). Cells were cultured on
100 mm Petri dishes, 1 3 106 cells/ml in 10 mL GM-CSF culture medium and allowed to differentiate for 7 days at 37C and 5 %
CO2. On days 3 and 5, the supernatant was removed, adherent cells were washed twice with PBS and 10 mL of fresh GM-CSF me-
dium was added. On day 7, cells showed differentiated morphology and expressed the macrophage markers CD11b+ F4/80+.
MC-38 cells, a cell line derived from a colon adenocarcinoma (kindly given to our group by Dr. Pedro Berraondo López, researcher
at Center for Applied Medical Research (CIMA), University of Navarre), were cultured in DMEMmedium (supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, and 10 % FBS) at 37C, in a 5 % CO2 atmosphere.
METHOD DETAILS
Transcriptomics analyses in human samples
Transcriptomic data from human CRC tissues were used to explore genes whose expression was associated with GZMA and GZMB
expression. Spearman’s correlation was calculated to generate a ranked gene list sorted by their level of co-expression with both
genes. Then, the Gene Set Enrichment analysis (GSEA) algorithm (Subramanian et al., 2005) was used on these pre-ranked lists
to identify enrichment in specific cellular functions and pathways. Specifically, the Hallmarks gene sets were interrogated.
The Gene Set Variation Analysis from GSVA R package was used to calculate an inflammatory score using the Positive Regulation
of Inflammatory Response gene set from Gene Ontology (GO). This function performs a non-parametric, unsupervised analysis for
estimating variation of the given gene sets through the samples in the expressionmatrix, returning an enrichment score for each sam-
ple. Also, a heat-map was plotted with all genes included in the gene set for visualization purposes (Figure S1A).
Spearman’s correlation was calculated to assess if there is a relationship between the inflammatory score and the GZMA/GZMB
expression. The same analysis was done stratifying samples into CMS subtyping. Linear regression models were also adjusted to
calculate R-squared and p values in each case.
To validate these results, an extended gene expression dataset was downloaded from GEO repository (GSE39582). This com-
prises 566 CRC human samples with distinct clinicopathological characteristics, which underwent surgery between 1987 and
2007. It includes patients from 0 to IV stage, bothMSI andMSS and receiving different treatments (Marisa et al., 2013). Finally, tumors
from both datasets were classify into the four consensus molecular subtypes CMS1 to CMS4 using the CMS classifier R package
(Guinney et al., 2015).
Induction of Colitis and Colitis-associated Colorectal Cancer
Induction of acute or chronic colitis and colitis associated colorectal cancer (CAC) was performed as previously described employing
a combination of DSS and AOM (Neufert et al., 2007; Wirtz et al., 2007). In brief, acute colitis was induced through administration of
2.5 % DSS (MW 36,000–50,000 from MP) in drinking water for five days. Chronic colitis was induced by 3 cycles of 2.5 % DSS in
drinking water for five days followed by normal drinking water for 2 weeks. Colorectal cancer was induced by intraperitoneal injection
of a single dose of the mutagenic agent AOM (10mg/kg, Sigma Aldrich) on day 1 followed by 3 cycles of 2.5%DSS in drinking water
for five days and normal drinking water for 2 weeks.
Clinical score
Mice were weighed and observed daily. The scoring system assigns severity scores to five different parameters: weight loss, stool
consistency, fecal blood, mouse behavior and dehydration. The final clinical score results from the addition of individual scoring, with
a maximum of 24 points per mouse. The scoring system assigns severity values to five parameters: Weight changes (< 1 % = 0; 1-5
%= 1; 5-10%= 2; 10-20%= 3; > 20%=4), Stool Consistency (Normal = 0; soft feces = 1; diarrhea = 4), Visible Bleeding (No visible =
0; visible bleeding = 4), Mouse Behavior (Normal = 0; slight changes = 1 abnormal = 4; immobility = 8) and Dehydration (Normal = 0;
dehydration = 4).Cell Reports 32, 107847, July 7, 2020 e3
Article
ll
OPEN ACCESSMacroscopic damage score
Animals were sacrificed, the colon was measured and weighed and the visible colonic damage was scored. The scoring system as-
signs severity values to six parameters: Diarrhea (normal = 0; soft = 1; liquid = 4), Bleeding (No = 0; Yes = 4), Erythema (No = 0; Mild
and/or localized = 1; intense and/or generalized = 2), Edema (No = 0; Mild and/or localized = 1; intense and/or generalized = 2), Ste-
nosis (No = 0; 1 Stenosis = 1; 2 Stenosis = 2; > 2 Stenosis = 3) and Adhesions (No adhesions = 0; Difficult dissection = 1; Visible ad-
hesions = 2; ..Wrapped.. intestine = 3). Similarly to clinical evaluation, the final macroscopic damage score was obtained by the addi-
tion of individual scoring. The incidence of tumors as well as number and tumor diameter when present were also quantified.
Histological Scoring of Inflammation and tumor grading
Colon tissues were removed from mice, fixed with 4 % paraformaldehyde, and embedded in paraffin. Sections from these samples
were stained with hematoxylin and eosin (H&E). Scoring of inflammation was performed according to previous works (Izcue et al.,
2008). Briefly, each sample was graded semiquantitatively from 0 to 3 for the four following criteria: degree of epithelial hyperplasia
and goblet cell depletion, leukocyte infiltration in the lamina propria, area of tissue affected, and presence of markers of severe
inflammation (such as crypt abscesses, submucosal inflammation, and ulcers). Scores for each criterion were added to give a final
quantification for intestinal inflammation ranging from 0 to 12. The total colonic score was calculated as the average of the individual
values from the colonic sections. Blinded samples were analyzed by an expert pathologist.
Low-grade dysplasia, high-grade dysplasia, and adenocarcinomawere blindly scored using criteria for grading dysplasia in human
IBD (Boulard et al., 2012), as well as the TNM classification of colorectal tumors (Sobin and Compton, 2010). Criteria for dysplasia in
human IBD: low grade dysplasia, requires intact tomild alteration of gland architecture and nuclear alterations that extend tomucosal
surface without appreciable loss of nuclear polarity; high grade dysplasia, involves intact to severe alterations of gland architecture
with clear evidence of a loss of nuclear polarity. TNM classification of colorectal tumors grades the level of tumor invasiveness, from
carcinoma in situ to invasion of submucosa. Photomicrographs of H&E and immunostained colon sections were taken with an Ax-
ioplan 2 microscope equipped with an AxioCamHRc camera and the Axiovision 4.6 image analysis software package (Zeiss).
Immunohistochemistry
Immunohistochemistry was carried out using the following antibodies: b-Catenin (1/300), anti-Ki-67 (1/200) and anti-Vimentin (1/100)
(all BD Biosciences), anti-pSTAT3 (Cell Signaling; dilution 1/200), and anti-SNAIL (tissue culture supernatant).
Immunohistochemical (IHC) analyses were performed using 3 mm sections of formaldehyde-fixed, paraffin-embedded tissue
blocks. Antigen retrieval was done by boiling the slides in 10mM sodium citrate pH = 6,6 for 10min (E-Cadherin, Ki-67 and Vimentin);
sub-boiling in 10 mM Tris base, 1 mM EDTA pH = 9 for 15 minutes (b-Catenin, SNAIL1) or sub-boiling for 15 minutes in 1 mM EDTA
pH = 8 (pSTAT3). Slides were blocked with filtered 5 % non-fat milk dissolved in PBS (in TBS plus 0.1 % Tween-20 in the case of
pSTAT3 and SNAIL).
In the case of SNAIL, after endogenous peroxidase-blocking cells were permeabilized with TBS containing 1% Triton X-100 and 1
% Tween-20 for 30 minutes at room temperature and washed twice with TBS plus 0.1 % Tween-20. For blocking, cells were incu-
bated 2 hours at room temperature with NGBS (10%Normal goat serum, 1%BSA, 0.1%Cold fish gelatin, 0.1% Triton X-100, 0.05
% Tween-20, 0.05 % sodium azide) (Francı́ et al., 2006).
Primary antibodies were diluted in PBS containing 1% BSA (except in the case of SNAIL for which 1% of NGBS was added to the
tissue culture supernatant of the hybridoma) and were incubated for 90 min at 37C or o/n at 4C. As secondary antibody, the cor-
responding HRP-labeled secondary antibody or anti-mouse or rabbit PowerVisionTM (Leica Biosystems) were used. The HRP color-
imetric substrate TMB (Vector) was used for visualization. Sections were counterstained with hematoxylin, dehydrated, and
mounted.
Positive cells were enumerated on 5 randomly chosen visual fields for each tissue sample with the aid of ImageJ software. For Ki-
67, the percentage of positively stained nuclei was determinates using the ImmunoRatio image analysis software, as an open source
of ImageJ plugin or as a freely accessed online program for image analysis from immunohistochemistry (Tuominen et al., 2010).
Immunohistochemistry stained slides were visualized and scanned on a ZEISS Axio Scan.Z1 at 20 X magnification.
Quantitative real-time RT-PCR
RNA extractions were carried out with the RNeasy mini kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions, as
previously described (Matheus et al., 2009). Total RNA was extracted from distal and proximal colonic tissue. cDNA was subse-
quently generated with SuperScript II reverse transcriptase (Invitrogen Life Technologies).
Quantitative real-time PCRwas performed with StepOne Plus PCR system (Invitrogen Life Technologies) in combination with spe-
cific primers for GZMA and COX-2 on the iQiCycler (Bio-Rad, Hercules, CA) according to a standard protocol (40 cycles, annealing
temperature 60C). Relative levels of mRNA expression were normalized to HPRTmRNA levels using a comparative method (2-DDCt).
Each sample was run in triplicate, and the mean Ct was determined. Relative GZMA expression under each experimental condition
(control or treatment) was expressed as DCt = CtGZMA - Ctcalibrator, being HPRT housekeeping gene expression used as calibrator.
Then relative GZMA mRNA expression was calculated as DDCt = DCtcontrol-DCttreatment. Finally, the relative gene expression levels
were expressed as fold difference (2-DDCt). All primer sequences are listed in the Key Resources Table.e4 Cell Reports 32, 107847, July 7, 2020
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Intestine pieces were cut out, weighed (30 mg) and maintained in culture medium (2 ml, DMEM containing 10 % FBS, 10 mM gluta-
mine, 10 mM HEPES and 100 U/ml of penicillin/streptomycin) at 37C in an atmosphere of 5 % CO2. After 24h, supernatants were
collected, centrifuged at 500 xg for 10 min and aliquots were stored at 80C for ELISA analysis (Han et al., 2010).
Levels of IL-1b, TNF-a, IFN-g, IL-6, IL-10 and IL-17 in supernatants were quantified with the respective Ready-SET-Go! ELISA Sets
from eBioscience. Prostaglandin E2 (PGE2) was analyzed with an ELISA kit from Arbor Assay following manufacturer’s instructions.
A conventional indirect sandwich ELISA to detect mouse GzmA has been previously described (Santiago et al., 2017).
Isolation of colon IEL cells and GzmA intracellular expression analysis
IEL cells from colon intestine were obtained from DSS/AOM treated mice and from untreated mice. In brief, a colon free of the lumen
were cut in small pieces and transferred to a 50mL conical tube with 20mL of pre-digesting solution (HBSS buffer containing 10%of
FBS, 5mMEDTA and 1mMDTT). The tissue was incubated at 37C for 25min with gentle shaking. After vortex sample vigorously for
10 s, intestinal fragments were removed by passing through a 100 mmcell strainer. Residual tissues were incubated again in the same
manner. Cell suspensions were pooled and washed with RPMI medium containing 10 % of FBS. To isolate a lymphoid cell fraction,
the cells were centrifuged in a 40%/80%Percoll gradient (Sigma Aldrich, Spain) at 700 xg for 20 min at room temperature. Cells from
the 40%/80% Percoll interface were collected, washed, and counted.
Colon IEL cells were stained with a combination of FITC conjugated anti CD3, APC conjugated anti CD8a, APC-Vio770 conjugated
anti NK1.1 and VioBlue conjugated anti CD45 antibodies fromMiltenyiBiotec. Subsequently, cells were fixed with paraformaldehyde
(PFA) 1%, then permeabilized with saponin 1% in PBS 5% FBS and incubated with PE conjugated anti GzmA (eBioscience) or with
the isotype (IgG-PE) (eBioscience). Finally, intracellular expression of GzmA was analyzed by FACS.
GzmA activity assay
GzmA protease activity on Bz-Pro-Phe-Arg-pNA-HCl (BACHEM) substrate was tested spectrophotometrically using Multi-ModeMi-
croplate Reader (Synergy HT, BioTek) as previously described (Martin et al., 2005). Briefly, 50 mL of supernatant from cultures of
colonic tissue explants were dissolved in 50 mL of 100 mM Tris/HCl; pH 8.5 (GzmA activity buffer). A soluble protein extract from
the CD8+ T cell line 1.3E6SN (cytotoxic T-lymphocyte line; CTLL), or from the mouse tumor cell line EL4.F15 used as positive and
negative controls, respectively. Then, Bz-Pro-Phe-Arg-pNA-HCl substrate (50 ml/well, end concentration 150 mM in GzmA activity
buffer) was added and incubated at 37C. Optical density (OD) at 405/490 nm was measured after 00; 600; 1200 and overnight. All
measurements were implemented by duplicate or triplicate. The specific activity of GzmA was represented as moles of substrate
converted by the enzyme per minute and per milligram of protein in a sample.
Expression and purification of recombinant GzmA and Serpinb6b
Recombinant mouse GzmA was produced in E.coli B834 (DE3) and purified by cation-exchange chromatography as previously
described for GzmB (Pardo et al., 2007). GzmA was produced as an inactive pro-enzyme (proGzmA), which was then activated
by cathepsin C to generate the active enzyme. Enzymatic activity of all preparations was analyzed as described above.
Recombinant mouse Serpinb6b was produced as His-tagged protein in P. Pastoris (SMD1163) and purified by immobilized metal
(Nickel) affinity chromatography as previously described (Kaiserman et al., 2014).
Analysis of IL-6 expression induced by extracellular GzmA in M1 macrophages
Recombinant mouse GzmA and Serpinb6b were produced in E.coli and P. Pastoris as previously described (Kaiserman et al., 2014;
Pardo et al., 2007). Pro-inflammatory M1 macrophages were generated from bone marrow using GM-CSF as growth factor.
Macrophages were stimulated with active GzmA (300 nM) or GzmA inactivated with the specific inhibitor serpinb6b (2.4 mM) and
E. coli LPS 100 ng/ml. NF-kB, caspase-1 and COX-2 pathways were blocked with specific inhibitors of NF-kB (Celastrol), caspase-1
(VX765) or COX-2 (Celecoxib) during 1h before the addition of GzmA. IL-6 was measured by ELISA in cell supernatants after 24h.
In vivo treatments
Extracellular GzmAwas inhibited using a specificmouseGzmA inhibitor, serpinb6b. CRCwas induced as indicated above. On day 35
a group of mice were treated with five doses of serpinb6b 20 mg iv every other day. A group of mice were treated with serpinb6b
previously inactivated with trypsin as a control. Mice were sacrificed at day 49; macroscopic score, incidence, number, and size
of tumors were analyzed. A portion of colon was cultured as indicated above to determine the level of inflammatory cytokines.
In vivo TNFawas inhibited using a human TNF specific antagonist, Enbrel (etanercept). CRCwas induced as previously described.
On day 56 mice were treated with five daily doses of Enbrel (5 mg/kg ip). On necropsy, incidence, number, and size of tumors were
analyzed. In addition, a colonic tissue samples (30 mg) were cultured during 24 h, supernatant was collected and the levels of TNF-a
was quantified by ELISA.
In order to analyze the steady-state intestinal permeability in vivo, Wt and GzmAKO healthy mice were treated with FITC-dextran
dissolved in PBS (100 mg/ml). Each mouse received 44 mg/100 g of body weight by oral gavage with a needle attached to a 1 mL
syringe. After 4 h, mice were sacrificed and blood was collected, then serum was separated and stored at 4C in the dark. 100 mL ofCell Reports 32, 107847, July 7, 2020 e5
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spectrophoto fluorometry with an excitation of 485 nm following manufacturer’s instructions.
Western blot
MC-38 cells were seeded (13 106 cel/wells) in DMEMmedium (supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml
streptomycin, and 10 % FBS). After 4 h, cells were changed into DMEM medium without SFB, and cultured for 16 h at 37C. Sub-
sequently, the medium was removed and supernatant from recombinant mouse GzmA-stimulated macrophage (300 nM) or super-
natant from LPS-stimulated macrophage (100 ng/ml) were added. Supernatant from unstimulated macrophage were use as control.
As a positive control, 50 ng/ml of mouse IL-6 (Miltenyi) was added. The cells were lysed 15 minutes after the addition of the stimuli.
The concentration of total proteins was determined using Quick StartTM Bradford Protein Assay (BioRad). Finally, a western blot was
performed using the corresponding antibodies to visualize and quantify the expression of pSTAT3.
Gut microbiota composition
Faces from both Wt and GzmAKO were collected after gently perianal stimulation. After a complete mixing of the sample by vortex,
total DNA was obtained using the QIAamp DNA Mini Kit (QIAGEN, Germany), adequate controls of quality and concentration, DNA
samples were sent to the FISABIO institution (http://fisabio.san.gva.es) for massive sequencing of 16S rDNA amplicons of the V3 and
V4 regions were amplified with the appropriate primers (Quast et al., 2013). The primers sequences are listed in the Key Resources
Table.
Taxonomic affiliations were assigned using SILVA_release_119 database (Quast et al., 2013). The statistical analysis was per-
formed using R statistical software and open source libraries. The quantitative data of the reads were homogenized using their rela-
tive percentage from the total reads of each sample to facilitate the comparison between samples. Finally, Galaxy Huttenhower Plat-
form (http://huttenhower.sph.harvard.edu/galaxy) was used in order to calculate LefSe (LDA Effect Size) algorithm and to obtain
cladograms in which microbial taxa that explain significant differences among groups of samples were represented.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 5 software using the test indicated in the corresponding figure legends.
Data are presented as mean ± SEM. The difference between means of unpaired samples was performed using the two-way
ANOVA or the one-way ANOVA with Bonferroni’s post-test or using un-paired t test. Survival curves were compared using both
the log rank test and the Gehan-Wilcoxon test. The tumor incidence was analyzed using a Fisher’s exact test. The results are given
as the confidence interval (p), and are considered significant when p < 0.05. Biological replicates are considered as the number of
individual mice.
In human tumor samples Spearman’s correlation was calculated to assess the relationship between the inflammatory score and
theGZMA /GZMB expression. The same analysis was done stratifying samples into CMS subtyping. Linear regression models were
also adjusted to calculate R-squared and p values in each casee6 Cell Reports 32, 107847, July 7, 2020
